GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
-19.58%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$262M
AUM Growth
+$262M
(+15%)
Cap. Flow
+$92.5M
Cap. Flow
% of AUM
35.26%
Top 10 Holdings %
Top 10 Hldgs %
69%
Holding
37
New
10
Increased
10
Reduced
2
Closed
1
Top Buys
| 1 |
BLUE
bluebird bio
BLUE
|
$16.7M |
| 2 |
Neurocrine Biosciences
NBIX
|
$12.9M |
| 3 |
ADMS
Adamas Pharmaceuticals, Inc.
ADMS
|
$9.71M |
| 4 |
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
|
$7.93M |
| 5 |
Exelixis
EXEL
|
$7.45M |
Top Sells
| 1 |
TTHI
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
|
$1.65M |
| 2 |
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
|
$759K |
| 3 |
Lisata Therapeutics
LSTA
|
$404K |
Sector Composition
| 1 | Healthcare | 72.94% |
| 2 | Technology | 4.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ADMS
1
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $30.5M | 10.94% | 2,109,099 +671,764 | +47% | +$9.71M |
|
|
FPRX
2
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $23.4M | 8.38% | 575,000 +5,342 | +0.9% | +$217K |
|
3
Vanda Pharmaceuticals
VNDA
$279M
| $22.8M | 8.19% | 2,731,210 +631,109 | +30% | +$5.28M |
|
|
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
| $19.3M | 6.92% | 2,085,959 +671,032 | +47% | +$6.2M |
|
|
TTPH
5
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $16.9M | 6.07% | 3,653,200 +1,713,200 | +88% | +$7.93M |
|
|
BLUE
6
DELISTED
bluebird bio
BLUE
| $16.7M | 6% | +393,135 | New | +$16.7M |
|
|
7
Exelixis
EXEL
$10.1B
| $15.6M | 5.59% | 3,896,113 +1,863,619 | +92% | +$7.45M |
|
|
8
Neurocrine Biosciences
NBIX
$13.8B
| $12.9M | 4.62% | +325,300 | New | +$12.9M |
|
9
Vericel Corp
VCEL
$1.83B
| $12.4M | 4.44% | 2,110,738 +24,710 | +1% | +$145K |
|
|
CNXR
10
DELISTED
Connecture, Inc.
CNXR
| $10.6M | 3.79% | 4,127,232 | – | – |
|
11
Arcturus Therapeutics
ARCT
$462M
| $7.66M | 2.75% | 2,020,166 +7,544 | +0.4% | +$28.6K |
|
12
Aurinia Pharmaceuticals
AUPH
$1.58B
| $7.19M | 2.58% | 2,457,144 | – | – |
|
13
Xencor
XNCR
$580M
| $7.1M | 2.55% | +528,692 | New | +$7.1M |
|
14
Adverum Biotechnologies
ADVM
$64.6M
| $6.7M | 2.4% | +1,295,416 | New | +$6.7M |
|
|
CMRX
15
DELISTED
Chimerix, Inc.
CMRX
| $6.64M | 2.38% | +1,300,000 | New | +$6.64M |
|
|
RPTP
16
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
| $6.19M | 2.22% | 1,346,344 +63,817 | +5% | +$294K |
|
|
SGYP
17
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $6M | 2.15% | 2,175,000 +628,112 | +41% | +$1.73M |
|
|
OCRX
18
DELISTED
Ocera Therapeutics, Inc.
OCRX
| $5.77M | 2.07% | 1,963,777 | – | – |
|
|
PRTK
19
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $4.63M | 1.66% | 305,459 -50,000 | -14% | -$759K |
|
20
Apyx Medical
APYX
$75.3M
| $4.48M | 1.61% | 2,680,000 | – | – |
|
|
VIRX
21
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $4.46M | 1.6% | 8,250,000 | – | – |
|
|
ARDM
22
DELISTED
Aradigm Corp Common Stock
ARDM
| $4.45M | 1.6% | 1,002,962 | – | – |
|
23
Acadia Pharmaceuticals
ACAD
$4.38B
| $2.8M | 1% | +100,000 | New | +$2.8M |
|
24
Tenax Therapeutics
TENX
$27.3M
| $2.27M | 0.82% | 1,108,593 | – | – |
|
|
RXDX
25
DELISTED
Ignyta, Inc.
RXDX
| $1.94M | 0.7% | +287,173 | New | +$1.94M |
|